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Aims Angiotensin converting enzyme (ACE) inhibition reduces heart disease and vascular stiffness in
hypertension and leads to kinin accumulation. In this study, we analysed the role and importance of
two kinin receptor subtypes in angiogenesis during ACE inhibition in an in vitro model of angiogenesis
of the mouse heart.
Methods and results First, we analysed the angiogenic properties of bradykinin and enalapril on wild-
type C57Bl/6 and B2 receptor2/2 mouse heart under normoxia (21% O2) and hypoxia (1% O2) in vitro and
the contribution of B1 and B2 kinin receptors to this effect. Bradykinin induced dose-dependent endo-
thelial sprout formation in vitro in adult mouse heart only under hypoxia (1.7 fold, n ¼ 6, P , 0.05). The
B2 receptor mediated sprouting that was induced by bradykinin and vascular endothelial growth factor
(VEGF164; n ¼ 6, P , 0.05), but did not mediate sprouting that was induced by growth factors bFGF or
PDGF-BB. Enalapril induced sprouting through both the B1 and B2 kinin receptors, but it required the
presence of the B2 receptor in both scenarios and was dependent on BK synthesis. B1-receptor agonists
induced sprout formation via the B1 receptor (2.5 fold, n ¼ 6, P, 0.05), but it required the presence of
the B2 receptor for them to do so. Both B2-receptor and B1-receptor agonist-induced angiogenesis
required nitric oxide biosynthesis.
Conclusion The kinin B2 receptor plays a crucial role in angiogenesis that is induced by different vaso-
active molecules, namely bradykinin, ACE inhibitors, B1-stimulating kinin metabolites, and VEGF164 in
an in vitro model of angiogenesis of mouse heart under hypoxia. Therapeutic treatment of hyper-
tensive patients by using ACE inhibitors may potentially beneﬁt the ischaemic heart through inducing
B2-dependent heart neovascularization.
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1. Introduction
Angiotensin converting enzyme (ACE) inhibitors and
bradykinin (BK) have protective effects on ischaemic heart
disease and postischaemic brain injury.1,2 This may be
partially due to the reduction of ischaemia as a result of
angiogenesis3 and vasodilation3,4 during ACE inhibition.
ACE inhibitors are known to prevent kinin degradation5
and some of the properties of ACE inhibition, such as micro-
vascular growth, have been attributed to the accumulation
of BK.6
Kinins such as BK are released by the kallikrein–kininogen
system and induce vasodilation and inﬂammation and modu-
latevasculargrowth.Thebiologicalactionof kinins ismediated
by at least two known G-protein-coupled receptors, the B1
receptors and B2 receptors.7 BK exerts most of its effects via
the B2 receptor that is constitutively expressed in the vascula-
ture. In contrast, the B1 receptor has a higher afﬁnity for kinin
metabolites, such as [des-Arg9]-BK and [des-Arg10]-kallidin,
and is expressed during tissue injury or inﬂammation.8 Kinin
receptor activation signals through NO-cGMP and prostacy-
clin-AMP pathways, modulating a broad spectrum of cellular
functions.9
ACE inhibitors have been shown to induce angiogenesis
via B2 receptor signalling in hindlimb ischaemia in mice.10,11
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In line, BK promotes angiogenesis through B2 receptor signal-
ling by increasing vascular permeability, and vascular endo-
thelial growth factor (VEGF),12 and B2-receptor antagonism
reduces angiogenesis and tumour growth in rats.13 Our pre-
vious studies have demonstrated that angiotensin II (Ang
II)-induced angiogenesis in vitro is mediated via an AT2-B2
receptor pathway through an Ang II-stimulated BK release,
too.14 However, BK stimulation has also been shown to
increase endothelial cell proliferation through the B1 recep-
tor via the nitric oxide (NO) pathway.15 Similarly, ischaemia
has been shown to induce new functional blood vessels
through the B1 receptor and to lead to limb post-ischaemic
recovery in mice.16 In the same study, both the B1 receptor
and the B2 receptor mediated angiogenesis in response to
local delivery of the human-tissue kallikrein gene,16 similar
as in models of rat sponge implants,17 and in corpora lutea.18
Thus, both kinin receptors, either individually or together,
have been shown to play a role in angiogenesis during ACE
inhibition or the local delivery of kinins.
In the present study, we, therefore, further analyse the
role, importance, and crosstalk of the two kinin receptor
subtypes in angiogenesis during ACE inhibition by using an
in vitro model of angiogenesis in mouse heart under
hypoxia.14,19
2. Methods
2.1 Animals
Twelve- to 14-week-old C57Bl/6 mice (Jackson Laboratories; wild
type and B2 receptor2/2) were used for angiogenesis in vitro
assay. The animals were euthanized, the hearts transferred to
PBS, and processed within half an hour post mortem as previously
described.19 All experiments conform with the Guide for the Care
and Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85-23, revised 1996), were in
accordance with the Swiss Federal Act on Animal Protection
(1998) and were approved by the Veterinary Department of the
Kanton of Basel-Stadt (Switzerland).
2.2 Angiogenesis in vitro assay
Weused a technique for three-dimensional in vitro angiogenesis assay
that we have developed and described in detail in earlier studies.14,19
In brief, 0.5–1 mm3 of tissue from the left ventricular myocardium of
mouse hearts were embedded into stabilized ﬁbrin-gels (Sigma-
Aldrich, Buchs, Switzerland) in 48 well plates. Heart explants were
incubated with a stimulant with or without inhibitors under normoxia
(21% O2) or hypoxia (1% O2) for 7 days. Stimulants or inhibitors were
added every other day: mouse VEGF164 (R&D systems); human basic
ﬁbroblast growth factor (bFGF)(R&D systems); human platelet-
derived growth factor-BB (PDGF-BB) (R&D systems); HOE140
(Sigma-Aldrich AG); BK Acetate, [Lys-des-Arg9]-BK, [des-Arg9]-BK,
[des-Arg10]-HOE140, and Lys-(des-Arg9, Leu8)-BK triﬂuoroacetate
salt (Sigma-Aldrich AG), PKSI-527 (Wako Chemicals), ZM323881 (Cal-
biochem), GSNO (Sigma-Aldrich), and NO synthase inhibitors
(Sigma-Aldrich AG). After 7 days of culture, endothelial sprouts
were photographed digitally (ColorView II-Soft Imaging System) on
an inverted light microscope (Olympus IX50) and pictures enhanced
digitally by ImageJ-software (Wayne Rasband, NIH, MD, USA).
Sprout formation was calculated and averaged by two indepen-
dent investigators by comparing samples in octuplicates for each
condition with a standardized scale (angiogenic index as determined
by computer assisted morphometric quantiﬁcation AnalySIS Pro, Soft
Imaging System) as described previously.19,20 Outgrowing cells and
sprouts were characterized by immunostainings with speciﬁc endo-
thelial cell marker GSL I-IB4 (20 mg/mL; Rectolab).
19
2.3 Nitric oxide production assay
NO concentration in the medium from cultured organ explants were
measured by using a ﬂuorometric nitrite assay21 with the NO Assay
kit according to the manufacturer’s speciﬁcations (Calbiochem,
Basel, Switzerland). Nitrite accumulated in supernatants was
detected by ﬂuorescence in a plate reader (Spectra Max analyzer,
Bucher Biotech AG, Basel).
2.4 Western blotting analysis
Heart tissuewas incubatedduring24and48 hand lysed inRIPAbufferas
describedpreviously.22After SDS–PAGE,proteinsweretransferredonto
a polyvinylidene ﬂuoride membrane (Millipore). The membrane was
blocked with 4% skim milk powder in a TBS-Tween solution and then
probed with polyclonal anti-B1 (M-19, Santa Cruz Biotechnology, CA,
USA), monoclonal anti-b-actin (AC-15, Sigma), and ﬁnally HRP-
conjugated IgGs (Cell Signalling Technology) to visualize proteins
bands by chemiluminescence (Amersham).
2.5 Statistical analysis
All results represent experiments repeated using heart explants
from at least ﬁve different mice. Data points in the results represent
the mean+ SEM. Statistical analysis was performed with SPSS for
Mac OS X (SPSS Inc.). Statistical signiﬁcance (P , 0.05) was com-
puted by using the Kruskal–Wallis and the Mann–Whitney tests for
non-parametric analysis and then corrected for multiple compari-
sons by using the Dunn’s test.
3. Results
3.1 Angiogenic properties of BK and enalapril
Under normoxia, no angiogenic response was elicited. In
hypoxia (1% O2), however, BK (1028 mol/L), enalapril
(1027 mol/L), and VEGF164 (10 ng/mL) induced a signiﬁcant
angiogenic response (1.4-, 1.4-, and 2.0-fold, respectively),
compared with the negative control P, 0.05 (Figure 1A
and B) in heart pieces from wild-type mice. This ﬁnding is sup-
ported by the results of earlier studies.14,19,23 Because hypoxia
was clearly a pre-requisite for in vitro angiogenesis of mouse
heart, all of the remaining experiments were performed
under hypoxia. The angiogenic index under hypoxia without
further stimulation varied between hearts derived from indi-
vidual mice and ranged from 0.5 to 1.5.
BK-induced endothelial sprouting under hypoxia was dose
dependent (1029–1026 mol/L BK). A plateau of maximal
angiogenic effect of BK was observed at concentrations
beyond 1026 mol/L (2.25+0.15, n ¼ 5, P , 0.05) in pieces
of heart from wild-type mice (Figure 1C).
3.2 Contribution of B1 and B2 receptors
in sprout formation
Blocking theB2 receptor completely bluntedBK-induced sprout
formation (P, 0.05) to control levels, whereas blocking the B1
receptor had no effect (P¼ NS) (Figure 2A). Combining both
antagonists did not further reduceBK-induced sprout formation
when compared with B2-receptor antagonism (Figure 2A).
Accordingly, in heart explants from B2 receptor2/2 mice, BK
did not induce sprouting above control levels at any concen-
tration of BK in a range from 10210 to 1027 mol/L compared
with dose-dependent BK-induced sprouting in explants from
wild-typemice (Figure 2B). Thus, BK-induced sprout formation
in pieces of mouse heart under hypoxia is speciﬁcally mediated
through the B2 receptor.
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Interestingly, VEGF did not induce sprouting in B2
receptor2/2 mouse heart explants either, whereas two
other potent angiogenic molecules, bFGF (10 ng/mL) and
PDGF-BB (10 ng/mL), induced sprouting in B2 receptor2/2
hypoxic pieces of mouse heart as strongly as they did in wild-
type pieces of mouse heart. Hypoxia-induced angiogenesis in
controls was also reduced in B2 receptor2/2 heart explants
when compared with those obtained from hypoxia-induced
angiogenesis in wild-type heart explants (Figure 2B).
Both B2-receptor and B1-receptor antagonists, alone or in
combination reduced VEGF164-induced sprout formation in
hypoxic heart explants (Figure 2C). VEGF164 is a ligand for the
receptor tyrosine kinase receptors, Flt-1 and Flk-1 responsible
for the angiogenic effects of VEGF164.
24 The addition of the
VEGF receptor kinase inhibitor ZM323881alsobluntedVEGF164-
induced sprout formation. However, bFGF (10 ng/mL)-induced
sprout formation was not affected in the presence of the
B2-receptor antagonist HOE140 (1027 mol/L) and the B1-
receptor antagonist [des-Arg10]-HOE 140 (1027 mol/L),
respectively (data not shown).
Taken together, these results suggest that both BK and
VEGF164 require the B2 receptor for in vitro angiogenesis in
hypoxic mouse heart explants, but bFGF and PDGF-BB do not.
3.3 ACE inhibition effect on sprout formation
We next assessed the angiogenic effects exerted through inhi-
bition of BK degradation by using the two ACE inhibitors ena-
lapril and perindopril. Physiological concentrations of these
ACE inhibitors induced sprout formation in mouse heart
explants under hypoxia, peaking at 1027 mol/L for enalapril
and at 1025 mol/L for perindopril (Figure 3A). Higher and non-
physiological concentrations of ACE inhibitors showed lesser
angiogenic effects that may be related to the anti-angiogenic
effects of metalloproteinase activity inhibition.25 Pre-
incubation of the heart explants with the speciﬁc kallikrein
inhibitor PKSI-527 (1025 mol/L) completely inhibited
enalapril-induced angiogenesis (Figure 3B). Since inhibition
of kallikrein blocks the conversion of kininogens into kinins,
latter result suggests that ACE-induced angiogenesis requires
kinin-induced signalling. HOE140 (1027 mol/L), the selective
B2-receptor antagonist, reduced enalapril-induced sprout
formation signiﬁcantly. The selective B1-receptor antagonist,
[des-Arg10]-HOE14026 (1027 mol/L), inhibited sprout for-
mation to a similar extent (Figure 3C). The combination of
both antagonists did not further inhibit enalapril-induced
sprout formation (Figure 3C). The same results were obtained
Figure 1 BK induces sprout formation in vitro. (A) Pieces of mouse heart stimulated with BK (1028 mol/L), enalapril (1027 nmol/L), mrVEGF164 (10 ng/ml), or
diluent control under normoxia (21% O2) or hypoxia (1% O2). (B) Quantiﬁcation of endothelial sprout formation after stimulation with BK (10–8 mol/L), enalapril
(1027 nmol/L), or mrVEGF164 (10 ng/mL). Angiogenic index is equal to standardized scaled from zero to four that indicates the degree of sprout formation. Data
points represent the mean of ﬁve independent experiments+SEM. *P , 0.05 vs. normoxia. #P , 0.05 vs. control diluent under hypoxia. (C) Quantiﬁcation of
endothelial sprout formation (angiogenic index) after stimulation of mouse heart with increasing concentrations of BK under hypoxia. Data points represent
the mean of ﬁve independent experiments+SEM. *P , 0.05 vs. negative control.
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when explants were stimulated with perindopril 1026 mol/L
(data not shown). Like BK, ACE inhibitors did not induce
sprout formation in pieces of B2 receptor2/2 mouse heart
(Figure 3D). These results indicate that angiogenesis induced
by ACE inhibitors under hypoxia is kinin-induced and can be
driven through either the B1 or B2 receptor, but requires the
presence of the B2 receptor for either scenario.
3.4 Activation of B1 receptors with B1 receptor
agonists
To assess the role of B1 receptor activation, we used selective
B1 receptor agonists.9 Both of the selective B1-receptor
agonists, ([des-Arg9]-BK and [des-Arg10]-kallidin, induced
sprout formation in the mouse heart explants under hypoxia
(2.5-fold increase with each B1 agonist at a concentration of
1027 mol/L, P, 0.05) (Figure 4A). As expected, incubation
with the selective B1-receptor antagonist [des-Arg10]-HOE140
blocked the angiogenic effect of the B1-receptor agonist
([des-Arg9]-BK, 1027 mol/L), whereas the B2-receptor antag-
onist HOE-140 had no effect (Figure 4B). The same results
were observed when we used the B1-receptor agonist
[des-Arg10]-kallidin (data not shown). However, B1-receptor
agonists did not induce any sprout formation in pieces of B2
receptor2/2mouseheart under hypoxia (Figure 4C) suggesting
that B1 receptor-induced angiogenesis requires the presence
of the B2 receptor.
Since B1-receptor expression is not constitutive but indu-
cible, we assessed the presence of B1-receptor protein in
the hypoxic mouse heart. B1 receptor protein was present
in both wild-type and B2-receptor2/2 mouse heart under
hypoxia, and its expression appeared to diminish after the
ﬁrst 24 h of incubation under normoxia (Figure 4D).
3.5 BK-induced sprouts resemble VEGF- but not
FGF-induced sprouting
We characterized sprout formation under hypoxia by analysing
the morphology and cell type. All tested vasoactive peptides
(BK, BK1-agonist), ACEI (enalapril), and angiogenic factors
(VEGF, bFGF, and PDGF-BB) induced organized sprouts and
tubes (Figure 5A). Speciﬁc endothelial marker, Alexa Fluor
labelled isolectin (GSL I-IB4), shows that these sprouts are com-
posed of endothelial cells (representative example shown for
B1 receptor-agonist and bFGF in Figure 5B).
BK-, B1 agonist-, and ACE inhibitor-induced sprouts were
more extended and show a low level of complexity and
branching (Figure 5A and B). Morphologically these sprouts
resemble those induced by VEGF164 (Figure 5A). On the
other side, bFGF- or PDGF-induced sprouting showed a
higher level of complexity, with thicker endothelial sprouts
and a higher level of network formation and branching.
Additionally unorganized single endothelial cells migrated
into the ﬁbrin matrix (Figure 5A and B).
3.6 Nitric oxide biosynthesis is required for B1
and B2 receptor-induced angiogenesis
Hypoxia signiﬁcantly induced NO biosynthesis as measured
by nitrite accumulation. BK (1027 mol/L) further stimulated
NO production under hypoxia. B2-receptor antagonist
HOE140 (1026 mol/L) blocked the increase in NO biosyn-
thesis (Figure 6A and B). B1-receptor antagonists but not
B2-receptor antagonists inhibited an increase in NO by the
B1-receptor agonist [des-Arg9]-BK (1027 mol/L) (Figure 6B).
NO synthase inhibitorswereaddedprior to stimulation of the
heart pieces with bradykinin (1028 mol/L) or [des-Arg9]-BK
(1028 mol/L). All of the NO synthase inhibitors tested,
L-NAME (1027 mol/L), L-NIO (1026 mol/L), L-NIL (1027 mol/L),
1400W (1027 mol/L), and SMT (1027 mol/L), prevented
sprout formation by both BK and B1 selective receptor ago-
nists (Figure 6C and D). Incubation in the presence of L-NIL
(1027 mol/L) prevented ACE inhibitor-induced sprout for-
mation completely (data not shown). This effect was speciﬁc
of NO inhibition since addition of an exogenous NO donor,
S-nitrosoglutathione, GSNO (1025 mol/L) reverted the anti-
angiogenic effect of L-NAME (Figure 6E). Thus, kinin-induced
Figure 2 BK- and VEGF-induced sprout formation in vitro under hypoxia. (A)
Quantiﬁcation of endothelial sprout formation (angiogenic index) of pieces of
mouse heart was incubated with BK alone or in the presence of a selective
B2-receptor antagonist HOE-140 (1027 mol/L, B2 Ant) or a selective B1-receptor
antagonist [des-Arg10]-HOE140 (1027 mol/L, B1 Ant), or both, under hypoxia.
Data points represent the mean of ﬁve independent experiments+SEM.
*P , 0.05 vs. BK-stimulated heart under hypoxia; n.s.¼ not signiﬁcant. (B)
Quantiﬁcation of endothelial sprout formation (angiogenic index) of wild-type
or B2 receptor2/2 mouse heart explants stimulated with increasing concen-
trations of BK, mrVEGF164, bFGF, or PDGF-BB under hypoxia (1% O2). Data points
represent the mean of six independent experiments+SEM. *P, 0.05 vs. wild-
type heart. (C) Quantiﬁcation of endothelial sprout formation (angiogenic
index) ofmouseheartexplants incubatedwithmrVEGF164 aloneor in thepresence
of the selective B2-receptor antagonist HOE-140 (1027 mol/L, B2 Ant), the selec-
tive B1-receptor antagonist [des-Arg10]-HOE140 (1027 mol/L, B1 Ant), both B1-
and B2-receptor antagonists or VEGF inhibitor ZM323881 (1027 mol/L, VEGF Inh)
underhypoxia.Datapoints representthemeanofﬁve independentexperiments+
SEM. *P, 0.05 vs. VEGF164-stimulated angiogenesis under hypoxia.
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Figure 3 ACE inhibitor-induced sprout formation in vitro under hypoxia. (A) Quantiﬁcation of endothelial sprout formation (angiogenic index) of wild-type
mouse heart explants stimulated with increasing concentrations of an ACE inhibitor, either enalapril or perindopril under hypoxia. Data points represent the
mean of three independent experiments+SEM. *P , 0.05 vs. control diluent. (B) Quantiﬁcation of endothelial sprout formation (angiogenic index) of wild-type
mouse explants stimulated with enalapril alone or in the presence of PKSI-527 (1025 mmol/L), a speciﬁc kininogenase inhibitor, under hypoxia. Data points rep-
resent the mean of three independent experiments+SEM. *P , 0.05 vs. enalapril-induced angiogenesis under hypoxia. (C) Quantiﬁcation of endothelial sprout
formation (angiogenic index) of mouse heart explants incubated with enalapril alone or in the presence of either the selective B2-receptor antagonist HOE-140
(1027 mol/L) or the selective B1-receptor antagonist [des-Arg10]-HOE 140 (1027 mol/L) or both, under hypoxia. Data points represent the mean of three inde-
pendent experiments+SEM. *P , 0.05 vs. enalapril-induced angiogenesis under hypoxia. (D) Quantiﬁcation of endothelial sprout formation (angiogenic index)
wild-type and B2 receptor2/2 mouse heart explants stimulated with enalapril under hypoxia (1% O2). Data points represent the mean of six independent
experiments+SEM. *P , 0.05 vs. wild-type heart.
Figure 4 B1 receptor agonist-induced sprout formation in vitro under hypoxia. (A) Quantiﬁcation of endothelial sprout formation (angiogenic index) of mouse
heart explants stimulated with increasing concentrations of the B1 agonists [des-Arg9]-BK or [des-Arg10]-kallidin under hypoxia over a period of 7 days. Data
points represent the mean of six independent experiments+SEM. *P , 0.05 vs. control diluent. (B) Quantiﬁcation of endothelial sprout formation (angiogenic
index) of mouse heart explants incubated with [des-Arg9]-BK alone or in the presence of either the selective B1-receptor antagonist [des-Arg10]-HOE 140
(1027 mol/L) or the selective B2-receptor antagonist HOE140 (1026 mol/L) or both, under hypoxia over a period of 7 days. Data points represent the mean of
ﬁve independent experiments+SEM. *P , 0.05 vs. [des-Arg9]-BK-induced angiogenesis; n.s.¼ not signiﬁcant. (C) Quantiﬁcation of endothelial sprout formation
(angiogenic index) of wild-type and B2 receptor2/2 mouse heart explants stimulated with the B1-receptor agonists: [des-Arg9]-BK (1028 mol/L) or
[des-Arg10]-kallidin (1028 mol/L) under hypoxia over a period of 7 days. Data points represent the mean of six independent experiments+SEM. *P , 0.05 vs.
wild-type heart. (D) Quantiﬁcation of endothelial sprout formation (angiogenic index) of wild-type mice and B2 receptor2/2 mouse heart explants incubated
under 1% O2 or 21% O2 during 0, 24, and 48 h. B1 receptor expression was analysed by western blotting. b-actin expression is shown as the control.
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angiogenesis in vitro of heart explants depends on B1- or
B2-induced NO biosynthesis.
4. Discussion
In this study, we show that exogenous BK and inhibition of its
degradation by ACE inhibitors induce sprout formation under
hypoxia in a mouse heart organ culture model. By using selec-
tive B1 and B2 antagonists and heart tissue from B22/2 mice,
we demonstrate that ACE inhibition-induced sprout formation
in vitro is mediated through the B1 and B2 receptors. ACE
inhibitor-induced angiogenesis has been attributed to the B2
receptor in hypertensive rats27 and in rabbit hindlimb ischae-
mia,10 but also to the B1 receptor in coronary endothelium.28
ACE inhibitors have also been shown to directly bind and acti-
vate theB1 receptor in theabsenceofACE.29 Inour study, enzy-
matic activity of kallikrein, which liberates BK and kallidins
from kininogens, was additionally required for ACE inhibitor-
induced angiogenesis. Further, the physical presence of the
B2 receptor was required since no sprouts formed from B2
receptor2/2 mouse heart explants during ACE inhibitor and
B1-agonist stimulation. No biochemical evidence of a direct
binding of ACE inhibitors to the B2 receptor exists so far.30
Thus, we suggest that ACE-inhibitor-mediated kallidin and BK
accumulation activate B1 and B2 receptors, respectively,
and that the B2 receptor is required mandatory to induce
angiogenesis.
A possible explanation for this effect is the formation of
complexes between B1 and B2 receptors permitting the trans-
duction of the B1 receptor signal. Indeed, G-protein coupled
receptors can form complexes, i.e. AT2-B2 -,31 AT2–AT1
receptors,32 and also B1–B2.33 It has been demonstrated
that B1–B2 complex formation correlates with increased con-
stitutive and agonist-stimulated receptor signalling efﬁ-
cacy.33 In these in vitro studies, the B2-receptor antagonist
HOE-140 did notmodify heterocomplex formation, suggesting
that B1 agonist signals through the B1–B2 complex even in the
presence of B2 antagonists.33 In our B22/2 mouse heart
explants, evidently, heterocomplexes cannot form thus pre-
venting signalling through B1 receptor. However, technical
limitations of our model do not allow to demonstrate hetero-
dimerization of these receptors.
The role of B2 receptor in angiogenesis is not restricted to
kinin activation. Also, in vitro angiogenesis triggered by the
classic angiogenic molecule VEGF was absent in the B2
receptor2/2 mouse heart explants. This effect was speciﬁc
for VEGF-induced angiogenesis, since B2 receptor knockout
did not reduce bFGF- and PDGF-BB-mediated sprout for-
mation. The morphology of BK-induced and ACE inhibitor-
induced endothelial sprouts resembled the morphology of
VEGF-induced sprouts but not the morphology of FGF- or
PDGF-BB-induced sprouts. A mechanism that may explain
this observation is transactivation of the KDR/Flk-1 rece-
ptor by the B2 receptor, which leads to endothelial tube
formation34 and contributes to endothelial NO synthase acti-
vation35 in coronary endothelial cells.
Wealso found thatbothactivation of theB1 receptor and the
B2 receptor induced endothelial sprout formation through a
mechanism that requires NO biosynthesis. The pro-angiogenic
effects of ACE inhibitors have been associatedwith an increase
in NO synthase,10 and NO biosynthesis is a pre-requisite for
angiogenesis.14,36,37 Other mechanisms, e.g. antioxidant or
anti-inﬂammatory effects of ACE inhibitors may, however,
also contribute to angiogenesis by preserving NO.38
A physiological role of the B2 receptor in angiogenesis of
the heart has already been suggested, as myocardial capil-
laries display rarefaction of up to 38% in B2 receptor2/2
mice.39 These structural changes can affect cardiac remo-
delling and induce hypertension and cardiac hypertro-
phy.39,40 Moreover, B2 receptor2/2 mice have shown a
diminished cardioprotective response to ACE inhibitors.41
Our experimental model underlines the importance of the
kinin receptors in angiogenesis, identifying the B2 receptor
as a key receptor to vessel growth that affects not only
kinin signalling but also VEGF-induced angiogenesis. The
exact nature of the VEGF–B2 interaction as well as the
B2–B1 receptor interaction still needs to be clariﬁed.
Thus, treatment of hypertensive patients with ACE inhibi-
tors may improve ischaemic heart function through inducing
B2-dependent heart neovascularization. Pathological situ-
ations with a dysfunctional B2 receptor expression may not
receive adequate beneﬁt from this treatment.42 In con-
clusion, our experiments show that angiogenic effects of
ACE inhibition in the mouse heart in vitro require hypoxia
and the presence of both the B1 receptor and the B2
Figure 5 Morphology of the sprouts derived from pieces of mouse heart
under hypoxia. (A) Different angiogenic stimuli induce sprouts with different
morphology in pieces of mouse heart under hypoxia. BK- (10 nmol/L), des-
Arg9-BK- (10 nmol/L), enalapril- (100 nmol/L), VEGF164-(10 ng/mL), bFGF-
(10 ng/mL), and PDGF-BB-(10 ng/mL) induced sprouting was observed under
an inverted light microscope. Magniﬁcation 4. (B) Fixed des-Arg9-BK- and
bFGF-induced sprouts stained for endothelial cells by ﬂuorescein-conjugated
GSL-IB4 (green). Magniﬁcation 10.
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receptor with NO as a downstream effector. The presence of
the B2 receptor is essential for angiogenesis that is induced
by hypoxia, BK, kinin metabolites, ACE inhibition, and VEGF.
Further studies may reveal the nature of the interactions
between kinin receptors and its relevance to hypoxia-
induced and VEGF-induced angiogenesis in physiological
and pathological responses.
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